Microbiote intestinal et stéatopathie métabolique
2020
Cassard, Anne-Marie | Houron, Camille | Ciocan, Dragos
Non alcoholic fatty liver disease or NAFLD is a disease with a large spectrum of liver injury that could appear in overweight or obese individuals with a metabolic syndrome. However, among overweight or obese, only a subset of individuals develops severe forms of NAFLD. Thus, the susceptibility of NAFLD is related to cofactors that could be protective or conversely noxious. Studies carried out in rodent models have demonstrated that the intestinal microbiota is a cofactor with a causal role in NAFLD. The bacterial patterns as well as the metabolites produced by intestinal bacteria are directly involved in the mediation of their effects, although the mechanisms are far from being fully identified. Changing intestinal microbiota by using fibers, prebiotics or probiotics can prevent or improve NAFLD in murine models. The translation of these data to human therapeutics is encouraging but remains limited. Indeed, there is clearly a dysbiosis associated with the different stages of NAFLD. The first clinical trials performed in patients to improve NAFLD showed beneficial effects although their analysis remains complicated given the many confounding factors, such as the use of metformin or proton inhibitors. A first clinical trial using a metabolite from Akkermansia muciniphila, suggests that new therapeutic approaches will emerge in the coming years based either on the modulation of the intestinal microbiota directly or on the modulation of intestinal microbiota targets.
اظهر المزيد [+] اقل [-]الكلمات المفتاحية الخاصة بالمكنز الزراعي (أجروفوك)
المعلومات البيبليوغرافية
تم تزويد هذا السجل من قبل National Agricultural Library